Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

438
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
438
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

449
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
449
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

471
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
471
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

427
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
427
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

882
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
882
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

631
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
631

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liver stiffness at baseline as a marker of hepatocellular carcinoma in cirrhosis: A matched analysis.

World journal of gastrointestinal pathophysiology·2026
Same author

Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study.

Alimentary pharmacology & therapeutics·2026
Same author

Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunction-associated steatotic liver disease.

Frontiers in epidemiology·2026
Same author

Evolving prokinetic therapy: New targets and therapeutic opportunities in gastrointestinal motility disorders.

World journal of gastrointestinal pharmacology and therapeutics·2026
Same author

Metabolic dysfunction-associated steatotic liver disease and obstructive sleep apnea: A cohort analysis of prevalence and hepatic outcomes.

World journal of gastrointestinal pharmacology and therapeutics·2026
Same author

Distinct Serum and Tissue Markers Predict Fibrosis in Crohn's Disease.

Cells·2026

Related Experiment Video

Updated: Jan 13, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.3K

Managing Acute Severe Ulcerative Colitis in 2025 and Beyond.

Manjeet Kumar Goyal1, Syed Adeel Hassan2, Jeffrey Aaron Berinstein3

  • 1Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.

Current Gastroenterology Reports
|January 7, 2026
PubMed
Summary
This summary is machine-generated.

Acute severe ulcerative colitis (ASUC) management is evolving. New biomarkers and therapies like Janus kinase inhibitors show promise in reducing colectomy rates, but rigorous trials are needed for personalized treatment.

Keywords:
Acute severe ulcerative colitisColectomy.Cyclosporine rescueHospitalizationInfliximab rescueUlcerative colitisUpadacitinib rescue

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.7K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.6K

Related Experiment Videos

Last Updated: Jan 13, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.3K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.7K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.6K

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Clinical Therapeutics

Background:

  • Acute severe ulcerative colitis (ASUC) presents significant clinical challenges with suboptimal outcomes.
  • Despite advancements, colectomy rates remain high, indicating a need for improved therapeutic strategies.

Purpose of the Study:

  • To review recent evidence on optimizing medical strategies for ASUC.
  • Focus on reducing colectomy rates and enhancing patient outcomes.

Main Methods:

  • Synthesis of recent scientific literature and clinical studies.
  • Analysis of novel biomarkers, predictive models, and emerging therapeutic agents.

Main Results:

  • Novel biomarkers and predictive models aid in stratifying ASUC patients for colectomy risk.
  • Intensified infliximab dosing shows variable benefits; Janus kinase inhibitors offer potential but require more evidence.
  • Colectomy remains a critical intervention, highlighting the current therapeutic efficacy ceiling.

Conclusions:

  • Modern ASUC management emphasizes rapid risk stratification and tailored advanced therapies.
  • Future research should focus on rigorous trials of emerging agents and personalized prognostic tools.